TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Update on Notified Bodies designation under MDR / IVDR

Update on Notified Bodies designation under MDR / IVDR

Author: Jean Boudaud

The implementation of the new European MDR (2017/745), now in place since May 2021 and IVDR (2017/746) less than a year away, has proven to be a very challenging task for the whole sector.

Whilst significant efforts have been undertaken in the designation of Notified Bodies, availability and capacity for review and support under the new frameworks remain a key challenge for Industry. Let’s have a look at the progress made over the past year.

Update on NB designation

In comparison to the original total number of MDD Notified Bodies (126), only twenty (20) currently have MDR designation.

In the IVD space, where the magnitude of Regulatory changes is even more significant, the number of designated bodies under IVDR is also still vastly insufficient, with only five (5) NBs designated, down from thirty-nine (39) under the old IVDD.

Here is a summary of designation as of 1 July 2021:

NB Number Name Country MDR IVDR
.# NB 2265 3EC International a.s. Slovakia
✔
.# NB 2797 BSI Group The Netherlands B.V. Netherlands
✔
✔
.# NB 2409 CE Certiso Orvos- és Kórháztechnikai Ellenőrző és Tanúsító Kft. Hungary
✔
.# NB 1912 DARE!! Services B.V. Netherlands
✔
.# NB 0344 DEKRA Certification B.V. Netherlands
✔
✔
.# NB 0124 DEKRA Certification GmbH Germany
✔
✔
.# NB 2460 DNV Product Assurance AS Norway
✔
.# NB 0297 DQS Medizinprodukte GmbH Germany
✔
.# NB 0537 Eurofins Expert Services Oy Finland
✔
.# NB 0459 GMED France
✔
.# NB 0051 IMQ ISTITUTO ITALIANO DEL MARCHIO DI QUALITÀ S.P.A. Italy
✔
.# NB 0373 ISTITUTO SUPERIORE DI SANITA’ Italy
✔
.# NB 2862 Intertek Medical Notified Body AB Sweden
✔
.# NB 0483 MDC MEDICAL DEVICE CERTIFICATION GMBH Germany
✔
.# NB 0482 MEDCERT ZERTIFIZIERUNGS- UND PRÜFUNGSGESELLSCHAFT FÜR DIE MEDIZIN GMBH Germany
✔
.# NB 0050 National Standards Authority of Ireland (NSAI) Ireland
✔
.# NB 0598 (ex-0403) SGS FIMKO OY Finland
✔
.# NB 0197 TÜV Rheinland LGA Products GmbH Germany
✔
✔
.# NB 0123 TÜV SÜD Product Service GmbH Zertifizierstellen Germany
✔
✔
.# NB 2696 UDEM Adriatic d.o.o. Croatia
✔
Total count
20
5
Differential since May 2020
+7
+1

Table Source: https://ec.europa.eu/growth/tools-databases/nando/index.cfm?fuseaction=directive.notifiedbody&dir_id=34

Comparing these numbers with our 2020 NB update also illustrates the very slow progress made in the designation process in the last year. This is due to a range of factors that are directly related to the complexity in implementation (scale of requirements and lack of guidance under MDR/IVDR) as well as external factors such as Covid-19 and Brexit (with the removal of UK NBs from eligible Conformity Assessment bodies).

Limitations in the transitional arrangements

During the transition period, Notified Bodies designated to the old Directives (MDD and IVDD) can continue to issue certificates under these schemes until the Date of Application of the new Regulations.

Notified Bodies can then begin to issue certificates to the new regulations (IVDR and MDR) once they have been designated.

After the Date of Application of the Regulations, Notified Bodies are only able to issue certificates to new Regulations. So, in other words, certificates for new Medical Devices can now only be issued against MDR and certificates for IVDs can still be issued under IVDD for a limited time and may have limited validity (especially in situations of Classification changes).

More challenges ahead

Despite the progress achieved over the year in terms of designation of notified bodies under the new MDR and IVDR, concerns remain about the capacity of Notified Bodies, both in certifying products under the new Regulations and in renewing certificates issued under the old Directives.

There is a risk that the validity of existing certificates will gradually expire without being immediately replaced by certificates under the new MDR and IVDR, which could potentially lead to shortages of devices essential for healthcare. This shortage may impact of course devices supplied to Europe but also potentially supply of products in regions where EC certificates are used as equivalent evidence of conformity assessment (e.g., Australia), although most regulators that accept CE certificates have put contingency plans in place.

Clearly, challenges in the transitional implementation of the new Regulations are not over. Beyond the designation process, it is also worth highlighting that cooperation and collaboration in the post-market surveillance and vigilance phases will also affect capacity from all actors involved (both the Regulators and Industry). Let’s also not forget the uncertainty around the operational development of EUDAMED. Following the release of the actor module (see our EUDAMED is Live blog) functional developments are still required for most of the modules that are pivotal to the full implementation of the Regulations.

Navigating the ever-changing Regulations can be perplexing. Our team is here to support you in these challenging times. Reach out to initiate a conversation and see how we can support you.

If you would like further information or are in need of support for these systems, please contact us.

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Highly competent, knowledgeable, absolutely reliable and dedicated to the projects

    Europe based medium-sized biotech development company
    Senior Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for